Working at fintech company Stripe taught how to manage immense complexity within a regulated, legacy system. This experience of 'wrangling complexity' is surprisingly similar to the challenges in biology, making it excellent preparation for a career in biotech.

David Solomon's career from academia to VC to CEO highlights a key formula for biotech leadership: combining a disciplined, scientific approach with savvy corporate finance to effectively translate good science into innovative medicines for patients.

Contrary to startup culture, the best training for biotech leadership is gaining broad, cross-functional experience in a large, structured pharmaceutical company. This foundation provides the necessary depth and breadth to navigate the complexities of leading a smaller, resource-constrained biotech later on.

The transition from a leadership role at a large pharma company like Gilead to a biotech CEO involves a massive shift in scope. Instead of managing one large function with a large team, a biotech CEO is hands-on with every aspect of the company, from science to finance.

Investors don't look for a specific personality type in biotech founders. Instead, they use pattern recognition to identify a crucial trait: executional excellence. The ability to expertly manage the diverse functions of a biotech company—from clinical to CMC to regulatory—is paramount, and prior experience is the best indicator of this skill.

Kevin Pojasek credits his effectiveness to a deliberate 12-year journey through diverse roles—investing, company creation, research, and clinical operations. This broad experience allows a leader to understand how all parts of the company, from high-level strategy to detailed science, fit together.

Unlike a research scientist who focuses deeply on a single project, a biotech investor's work involves constant topic rotation. Their value comes from looking broadly across therapeutic areas and company stages, speaking with up to 10 companies a day to identify patterns and opportunities in a rapidly changing sector.

Sandeep Kulkarni's experience as a public market investor ingrained a constant awareness of capital allocation, competitive threats, and creating options. This external lens, often differing from a purely scientific founder's internal focus, helps in making pragmatic, value-driven decisions and navigating market dynamics.

Luba Greenwood argues that unlike in tech, many biotech CEOs lack P&L experience. In today's cash-constrained market, CEOs need to be able to build financial models and understand finance deeply to be effective, a skill she personally developed after transitioning from law and science.